GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NextCell Pharma AB (OSTO:NXTCL) » Definitions » Change In Receivables

NextCell Pharma AB (OSTO:NXTCL) Change In Receivables : kr4.31 Mil (TTM As of Feb. 2025)


View and export this data going back to 2017. Start your Free Trial

What is NextCell Pharma AB Change In Receivables?

NextCell Pharma AB's change in receivables for the quarter that ended in Feb. 2025 was kr0.99 Mil. It means NextCell Pharma AB's Accounts Receivable declined by kr0.99 Mil from Nov. 2024 to Feb. 2025 .

NextCell Pharma AB's change in receivables for the fiscal year that ended in Aug. 2024 was kr3.17 Mil. It means NextCell Pharma AB's Accounts Receivable declined by kr3.17 Mil from Aug. 2023 to Aug. 2024 .

NextCell Pharma AB's Accounts Receivable for the quarter that ended in Feb. 2025 was kr2.25 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. NextCell Pharma AB's Days Sales Outstanding for the three months ended in Feb. 2025 was 63.16.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. NextCell Pharma AB's liquidation value for the three months ended in Feb. 2025 was kr18.18 Mil.


NextCell Pharma AB Change In Receivables Historical Data

The historical data trend for NextCell Pharma AB's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NextCell Pharma AB Change In Receivables Chart

NextCell Pharma AB Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.01 -3.24 -1.56 -7.59 3.17

NextCell Pharma AB Quarterly Data
May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.57 -0.28 4.94 -1.33 0.99

NextCell Pharma AB Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Feb. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr4.31 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NextCell Pharma AB  (OSTO:NXTCL) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

NextCell Pharma AB's Days Sales Outstanding for the quarter that ended in Feb. 2025 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=2.248/3.248*91
=63.16

2. In Ben Graham's calculation of liquidation value, NextCell Pharma AB's accounts receivable are only considered to be worth 75% of book value:

NextCell Pharma AB's liquidation value for the quarter that ended in Feb. 2025 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=26.338-10.114+0.75 * 2.248+0.5 * 0.545
=18.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NextCell Pharma AB Change In Receivables Related Terms

Thank you for viewing the detailed overview of NextCell Pharma AB's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


NextCell Pharma AB Business Description

Traded in Other Exchanges
N/A
Address
Karolinska Institutet Science Park, Halsovagen 7, Huddinge, SWE, 14157
NextCell Pharma AB is a healthcare services provider. The company is engaged in the research of stem cell and is developing the candidate drug ProTrans for the treatment of diabetes and immunosuppression in kidney transplants.

NextCell Pharma AB Headlines

No Headlines